GordonMD Global Investments LP

BEVERELY HILLS, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$166.5M2026 Q3
Positions14
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.85.7%

GordonMD Global Investments LP reported 14 positions worth $166.5M as of September 30, 2026 (13F filed November 16, 2026). Largest holding: PYXS (21.8%).

10 / 14 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 PYXSPyxis Oncology$36.2M21.75%15,541,909——-32.2%
▸ 2 KYTXKyverna Therapeutics$30.7M18.47%4,521,318———
▸ 3 TEVATeva Pharmaceutical Industries$15.0M9.03%379,520——+7.5%
▸ 4 CLDXCelldex Therapeutics$9.1M5.45%279,720———
▸ 5 TNGXTango Therapeutics$9.0M5.42%1,852,495——-3.1%
▸ 6 VIRVir Biotechnology$9.0M5.40%803,552——-14.3%
▸ 7 ADRXADARx Pharmaceuticals$9.0M5.39%450,000——-28.8%
▸ 8 ALLOAllogene Therapeutics$8.5M5.09%5,298,000——-47.6%
▸ 9 BLCOBausch & Lomb$8.1M4.86%475,472——+22.8%
▸ 10 EDITEditas Medicine$8.0M4.83%3,127,000——-27.2%

Pro Feature

The remaining 4 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does GordonMD Global Investments LP hold as of Q3 2026?

GordonMD Global Investments LP reported 14 positions worth $166.5M in its Q3 2026 13F filing. Largest positions: PYXS (21.8%), KYTX (18.5%), TEVA (9.0%), CLDX (5.4%) and TNGX (5.4%).

What did GordonMD Global Investments LP buy in Q3 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did GordonMD Global Investments LP sell in Q3 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.